يعرض 1 - 20 نتائج من 320 نتيجة بحث عن '(( brain ((((nn decrease) OR (mean decrease))) OR (greatest decrease)) ) OR ( _ parp decrease ))', وقت الاستعلام: 0.61s تنقيح النتائج
  1. 1
  2. 2
  3. 3

    Inotodiol decreases clone formation in HCC cells. حسب Yushuang Xing (20636685)

    منشور في 2025
    "…In addition, inotodiol showed to induce apoptosis, characterized by an increase in Bax expression, a decrease in Bcl-2, Bcl-XL and MCL1 expression, the initiation of cleaved PARP1 and cleaved caspase 3, and inhibition of the MAPK/ERK pathway. …"
  4. 4
  5. 5
  6. 6

    Claudin V is decreased following infection with Mtb. حسب Amanda S. Latham (12093638)

    منشور في 2024
    "…Exposure to Mtb H37Rv and HN878 decreased claudin V expression compared to uninfected controls in the frontal cortex (E), cerebral nuclei (J), brain stem (O), thalamus (T), and hippocampus (Y). …"
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16

    Astrocytes increase contact with vessels and expression of AQP4 following Mtb infection, which is decreased in cytosis<sup>+</sup> animals. حسب Amanda S. Latham (12093638)

    منشور في 2024
    "…Decreased expression of AQP4, and endfoot contact, is found in cytosis<sup>+</sup> animals in the frontal cortex (D and E), cerebral nuclei (J and K), brain stem (P and Q), thalamus (V and W) and hippocampus (BB and CC). …"
  17. 17

    PARP9 knockdown promotes apoptosis and DNA damage. حسب Yating Li (1819822)

    منشور في 2024
    "…(E) DNA damage in GC cells significantly increased post-PARP9 knockdown as determined by comet assay. (F) The anti-DNA damage capacity of GC cells decreased markedly following reduction of PARP9 expression. …"
  18. 18
  19. 19
  20. 20

    Data Sheet 1_Imaging-based assessment of response to olaparib in platinum-sensitive relapsed ovarian cancer patients.pdf حسب Maria Delgado-Ortet (8840702)

    منشور في 2025
    "…In this work, we developed noninvasive imagingbased measurements of spatial and longitudinal heterogeneity in a retrospective analysis of a phase 2 non-randomized study of germline BRCA1/BRCA2 mutated (gBRCAm) ovarian cancer patients treated with combination of PARP inhibitors (PARPi) and immune checkpoint inhibitors (ICIs).…"